Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 72 | 1 | 78 | +7 |
| Shares | 23.4M | 1.76K | 26.6M | +3.20M (+13.7%) |
| Value | $299.9M | $23.0K | $512.9M | +$213.0M (+71.0%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Point72 Asset Management, L.P. | 312,461 | $6.02M | 0.03% |
| Belvedere Trading LLC | 168,588 | $3.52M | 3.81% |
| SEI Investments Co | 93,854 | $1.81M | 0.00% |
| Tri Locum Partners LP | 80,459 | $1.55M | 0.64% |
| Virtu Financial LLC | 36,003 | $693.0K | 0.06% |
| Alliancebernstein L.P. | 35,900 | $691.0K | 0.00% |
| Picton Mahoney Asset Management | 23,200 | $446.0K | 0.02% |
| Rhumbline Advisers | 16,174 | $312.0K | 0.00% |
| ExodusPoint Capital Management, LP | 16,013 | $308.0K | 0.00% |
| HAP Trading, LLC | 15,322 | $295.0K | 0.04% |
| Cutler Group LP | 7,711 | $148.0K | 0.02% |
| Walleye Trading LLC | 5,525 | $106.0K | 0.00% |
| Fred Alger Management, LLC | 5,129 | $99.0K | 0.00% |
| PEAK6 Investments LLC | 1,500 | $32.4K | 0.00% |
| Credit Agricole S A | 500 | $10.0K | 0.00% |
| Tradition Wealth Management, LLC | 500 | $10.0K | 0.00% |
| Glassman Wealth Services | 39 | $1.00K | 0.00% |
| Credit Suisse AG | 11 | $0 | 0.00% |
| Captrust Financial Advisors | 19 | $0 | 0.00% |
| TCI Wealth Advisors, Inc. | 21 | $0 | 0.00% |
Sold out (13)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Agf Investments Inc. | 160,000 | $2.06M |
| Renaissance Technologies LLC | 146,400 | $1.88M |
| Balyasny Asset Management LLC | 62,915 | $808.0K |
| Oasis Management Co Ltd. | 50,000 | $643.0K |
| PFS Investments Inc. | 39,558 | $508.0K |
| Atom Investors LP | 36,691 | $471.0K |
| Silverarc Capital Management, LLC | 30,000 | $386.0K |
| Walleye Capital LLC | 28,187 | $362.0K |
| Caas Capital Management LP | 17,000 | $218.0K |
| Squarepoint Ops LLC | 15,000 | $193.0K |
| Quantbot Technologies LP | 2,200 | $28.0K |
| Point72 Hong Kong Ltd | 1,159 | $15.0K |
| Northwestern Mutual Wealth Management Co | 300 | $4.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 1,763 | $23.0K |